Skip to content

Medical Therapy

TL;DR — Randomized evidence for slowing TAA exists only in Marfan syndrome, and it is modest: beta-blockade (Shores 1994) and ARBs (COMPARE, AIMS) each slow aortic-root growth by fractions of a millimeter per year, the head-to-head trial (Lacro 2014) found no difference between losartan and atenolol, and the individual-patient-data meta-analysis of 7 trials (Pitcher 2022) settled the saga: ARBs roughly halve the rate of root z-score increase, beta-blockers indirectly do about the same, effects appear additive — but no trial or meta-analysis has shown a reduction in dissection, surgery, or death. In non-Marfan/degenerative TAA there is no RCT showing any drug slows growth or prevents dissection; guideline pharmacotherapy is blood-pressure control (<130/80, beta-blocker first, ARB adjunct) on B-NR/C-level evidence. Meanwhile the drug-harm ledger is contested: fluoroquinolones carry a consistent ~1.5–2.5× association with aneurysm/dissection that active-comparator re-analyses largely attribute to confounding by infection and surveillance bias; calcium-channel blockers accelerated aneurysm in Marfan mice with an accompanying human association signal. Exercise advice (avoid heavy isometric lifting/Valsalva) rests on hemodynamic physiology and case series, not trials.

Marfan syndrome: the trial-by-trial record

Trial / study Design, n Comparison Aortic outcome Result
Shores 1994 (PMID 8152445) Open-label RCT, 70 adolescents/adults Propranolol (mean 212 mg/d) vs none, ~10 yr Regression slope of root dimension Slope 0.023 vs 0.084 per year (p<0.001); fewer clinical endpoints (5 vs 9, NS individually)
Brooke 2008 (PMID 18579813) Retrospective pediatric cohort, 18 ARB added after failed prior therapy Root growth rate 3.54±2.87 → 0.46±0.62 mm/yr (p<0.001) — hypothesis-generating, no controls
COMPARE 2013 (Groenink, PMID 23999449) Open-label RCT, blinded endpoints, 233 adults Losartan add-on vs none, 3 yr Root dilatation (MRI) 0.77±1.36 vs 1.35±1.55 mm/3 yr (p=0.014); no difference in clinical endpoints
Marfan Sartan 2015 (Milleron, PMID 25935877) Double-blind placebo-controlled RCT, 303 (86% on beta-blocker) Losartan add-on vs placebo, 3.5 yr Root diameter/z-score slope 0.44 vs 0.51 mm/yr (p=0.36) — negative
Lacro 2014 (PMID 25405392) RCT with blinded core-lab endpoints (dose-titrating staff unblinded), 608 children/young adults (6 mo–25 yr), NCT00429364 Losartan vs atenolol, 3 yr Root z-score slope −0.107 vs −0.139 SD/yr (p=0.08): no difference; both arms' z-scores fell; no difference in death/dissection/surgery
AIMS 2019 (Mullen, PMID 31836196) Double-blind placebo-controlled RCT, 192 (6–40 yr, 56% on beta-blocker) Irbesartan vs placebo, up to 5 yr Root diameter slope (echo, core lab) 0.53 vs 0.74 mm/yr; difference −0.22 mm/yr (95% CI −0.41 to −0.02; p=0.030)
Pitcher 2022 IPD meta-analysis (PMID 36049495) 7 RCTs, 1,442 patients without prior aortic surgery (a) ARB vs control, 4 trials n=676; (b) ARB vs beta-blocker, 3 trials n=766 Annual change in root z-score (a) 0.07 vs 0.13 SD/yr — ARB halves progression (difference −0.07; p=0.012), larger effect in pathogenic FBN1 variants (heterogeneity p=0.005), independent of beta-blocker use; (b) ARB ≈ beta-blocker (p=0.48); indirect beta-blocker vs control −0.09 SD/yr (p=0.042)

Interpretation the IPD authors themselves draw: both classes work modestly, effects are likely additive, and combination therapy from diagnosis "would be expected to lead to a delay in the need for aortic surgery" — an extrapolation from a surrogate, since no randomized evidence shows fewer dissections or deaths (Pitcher 2022, PMID 36049495). The 2022 ACC/AHA guideline translates this into: beta-blocker or ARB at maximally tolerated dose, Class 1, LOE A — one of the very few LOE A recommendations anywhere in the document — and both together, 2a C-LD (Isselbacher 2022, PMID 36322642). Deep notes: literature/notes/shores-1994-propranolol.md, lacro-2014-losartan-vs-atenolol.md, pitcher-2022-ipd-meta.md.

The losartan saga in one paragraph

Habashi 2006 showed that losartan prevented aneurysm in fibrillin-1-mutant Marfan mice, in association with reduced TGF-β signaling — a mechanism-based cure narrative that electrified the field (Habashi 2006, PMID 16601194; mechanism: pathophysiology). A tiny uncontrolled pediatric series appeared to replicate it (Brooke 2008, PMID 18579813). Then adequately powered trials delivered: benefit as add-on in adults (COMPARE; Groenink 2013, PMID 23999449) but not in the placebo-controlled French trial (Milleron 2015, PMID 25935877), no superiority over atenolol in the largest trial (Lacro 2014, PMID 25405392), modest benefit of irbesartan (Mullen 2019, PMID 31836196), and finally the IPD synthesis: real, class-level, surrogate-endpoint, ~50%-of-a-small-number effect (Pitcher 2022, PMID 36049495). The mouse-to-human discount here is a canonical case study for animal models.

Secondary signals worth tracking, both hypothesis-generating: long-term COMPARE follow-up (median 8 yr) found fewer deaths (0 vs 5) and dissections (3 vs 11) in continued-losartan patients (van Andel 2020, PMID 32548624); and losartan benefit concentrated in FBN1 haploinsufficient (0.5 vs 1.8 mm/3 yr, p=0.001) rather than dominant-negative genotypes (Franken 2015, PMID 25613431) — though the IPD analysis found the ARB effect in pathogenic-variant carriers generally (Pitcher 2022, PMID 36049495).

How solid was the beta-blocker foundation?

A 2006 meta-analysis (6 studies, 802 patients, only one randomized) found no evidence of clinical benefit — patients on beta-blockers were, if anything, more likely to reach an endpoint (fixed-effects OR 1.50, 95% CI 1.05–2.16), driven by confounded observational cohorts (Gersony 2006, PMID 16831475). The best randomized support remains Shores 1994 (surrogate slope, n=70, open-label) plus the indirect estimate from the IPD meta-analysis (−0.09 SD/yr, p=0.042; Pitcher 2022, PMID 36049495). Beta-blockade in Marfan is therefore better supported in 2022 than in 2006 — but by triangulation, not by a definitive trial.

Non-Marfan / degenerative TAA: the evidence vacuum

No randomized trial has shown that any medication slows growth or prevents dissection in sporadic/degenerative TAA. The 2022 guideline's pharmacology for sporadic TAA is explicitly blood-pressure therapy:

Recommendation (sporadic TAA) COR LOE
Antihypertensive therapy if average SBP ≥130 or DBP ≥80 mm Hg, to reduce cardiovascular events 1 B-NR
Beta-blockers to achieve BP target, regardless of aneurysm cause 2a C-LD
ARB as adjunct to beta-blocker to achieve BP target 2a C-EO

(Isselbacher 2022, PMID 36322642.) Note what these are not: disease-modifying claims. The stated goal is "to slow growth and prevent aortic dissection, as well as to reduce nonaortic cardiovascular events," but the evidence grade concedes the first two are extrapolated — from hypertension's role as a dissection risk factor, from SPRINT-style BP outcome data in general cardiovascular disease, and from Marfan biology (Isselbacher 2022, PMID 36322642). Smoking cessation and atherosclerotic risk-factor control ride along on general cardiovascular grounds (Isselbacher 2022, PMID 36322642).

Statins: benefit demonstrated in Marfan mice (pravastatin reduced aneurysm growth via Ras/ERK inhibition; Sato 2018, PMID 30571378); no randomized human TAA data. Human support is observational/indirect only and was not verified here beyond the preclinical work — statins in TAA patients are prescribed for coexisting atherosclerotic indications, not for the aneurysm.

Drugs under suspicion of harm

Fluoroquinolones — a live controversy

Mechanistic prior: fluoroquinolones are associated with collagen degradation (tendinopathy/rupture), plausibly extending to aortic matrix (Lee 2015, PMID 26436523).

Study Design Headline estimate
Lee 2015 (PMID 26436523) Taiwan NHIRD nested case-control (1,477 cases / 147,700 controls) Current use RR 2.43 (1.83–3.22) for aneurysm/dissection; past use RR 1.48
Lee 2018 (PMID 30213330) Case-crossover, 1,213 hospitalized AA/AD patients OR 2.71 (1.14–6.46); dose-duration gradient (OR 2.83 for >14 d)
Pasternak 2018 (PMID 29519881) Swedish cohort, 360,088 fluoroquinolone episodes propensity-matched to amoxicillin HR 1.66 (1.12–2.46) within 60 d; driven by aneurysm (HR 1.90), not dissection (HR 0.93); absolute excess 82 cases/1M episodes
Dong 2020 (PMID 32897358) Taiwan, 28,948 cases; compares infections and comparator antibiotics Indicated infection itself: OR 1.73 (septicemia 3.16); fluoroquinolone vs amoxicillin-clavulanate/ampicillin-sulbactam OR 1.01 (0.82–1.24); vs extended-spectrum cephalosporins OR 0.88 — null
Gopalakrishnan 2020 (PMID 32897307) US claims; disease-matched active comparators vs azithromycin (pneumonia) HR 2.57; vs TMP-SMX (UTI) HR 0.99; vs amoxicillin HR 1.54 → attenuates to 1.13 (0.96–1.33) when baseline aortic imaging is required — consistent with surveillance bias; absolute rates <0.1%

Synthesis: the unadjusted association is reproducible; whether it is causal is genuinely unresolved because sicker, more-imaged patients get fluoroquinolones. The 2022 ACC/AHA guideline cites the association only in its research-gaps section ("pathways... are unknown") and issues no formal avoidance recommendation (Isselbacher 2022, PMID 36322642). Pragmatic middle ground in practice: prefer alternatives in patients with known aneurysm/dissection when equally effective, and do not withhold fluoroquinolones for serious indicated infections — the position argued by the comparator studies themselves (Dong 2020, PMID 32897358; Gopalakrishnan 2020, PMID 32897307).

Calcium-channel blockers in Marfan

In Marfan mice, CCBs (amlodipine/verapamil class) accelerated aneurysm expansion, rupture, and death via ERK1/2- and AT1R-dependent PKCβ signaling; in an accompanying human analysis, Marfan and other inherited-TAA patients taking CCBs had increased risk of aortic dissection and need for aortic surgery compared with patients on other antihypertensives (Doyle 2015, PMID 26506064). Observational and confounded — but with a concordant mechanism, enough to make CCBs a second-line choice in heritable aortopathy (see syndromic aortopathies).

Exercise and lifestyle restrictions

  • Physiology: heavy lifting with Valsalva can drive SBP transiently above 300 mm Hg (Isselbacher 2022, PMID 36322642).
  • Case evidence: 31 acute dissections in the context of severe exertion (predominantly weightlifting), 30/31 male, mean age 47, mean aortic diameter only 4.63 cm, 27/31 ascending; 32% died. Moderate aortic dilation appears to confer vulnerability to exertion-triggered dissection at sizes far below surgical thresholds (Hatzaras 2007, PMID 16847387).
  • Guideline (all C-EO, i.e., expert opinion): educate patients with significant aortic disease to avoid intense isometric exercise (heavy weightlifting/Valsalva), burst exertion, and collision sports (COR 1); cardiac rehabilitation after aortic surgery (COR 1); light weightlifting and low-intensity aerobic activity are considered safe and beneficial; there is explicitly "no uniform consensus" on intermediate intensities, and no trial or robust longitudinal evidence quantifies exercise-associated aortic risk (Isselbacher 2022, PMID 36322642).

Open questions

  • Does any medical therapy prevent hard endpoints (dissection, surgery, death) in Marfan? All randomized evidence is surrogate root-growth data; the only hard-endpoint signal is non-randomized long-term follow-up (van Andel 2020, PMID 32548624; Pitcher 2022, PMID 36049495).
  • Is there any drug worth trialing in degenerative TAA — and can a trial be powered given growth of ~0.1 cm/yr and measurement error of similar magnitude? (Davies 2002, PMID 11834007; Isselbacher 2022, PMID 36322642).
  • Is the fluoroquinolone-aorta association causal? Head-to-head comparator designs disagree with unexposed-comparator designs; a trial is infeasible and a definitive quasi-experimental design has not been produced (Pasternak 2018, PMID 29519881; Dong 2020, PMID 32897358; Gopalakrishnan 2020, PMID 32897307).
  • Do genotype-stratified responses (FBN1 haploinsufficient vs dominant-negative) justify genotype-guided therapy? One COMPARE substudy supports it; the IPD analysis found variant-positive patients benefit more, but stratified prescribing has never been tested (Franken 2015, PMID 25613431; Pitcher 2022, PMID 36049495).
  • Are CCBs actually harmful in human heritable aortopathy, or is the association confounding by indication? (Doyle 2015, PMID 26506064).
  • What exercise dose is safe? Current limits are expert opinion plus case series at mean 4.63 cm (Hatzaras 2007, PMID 16847387; Isselbacher 2022, PMID 36322642).

References

  1. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330:1335-1341. PMID 8152445. doi:10.1056/NEJM199405123301902
  2. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117-121. PMID 16601194. doi:10.1126/science.1124287
  3. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med. 2008;358:2787-2795. PMID 18579813. doi:10.1056/NEJMoa0706585
  4. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial (COMPARE). Eur Heart J. 2013;34:3491-3500. PMID 23999449. doi:10.1093/eurheartj/eht334
  5. Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015;36:2160-2166. PMID 25935877. doi:10.1093/eurheartj/ehv151
  6. Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371:2061-2071. PMID 25405392. doi:10.1056/NEJMoa1404731
  7. Mullen M, Jin XY, Child A, et al. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. Lancet. 2019;394:2263-2270. PMID 31836196. doi:10.1016/S0140-6736(19)32518-8
  8. Pitcher A, Spata E, Emberson J, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022;400:822-831. PMID 36049495. doi:10.1016/S0140-6736(22)01534-3
  9. van Andel MM, Indrakusuma R, Jalalzadeh H, et al. Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the COMPARE trial. Eur Heart J. 2020;41:4181-4187. PMID 32548624. doi:10.1093/eurheartj/ehaa377
  10. Franken R, den Hartog AW, Radonic T, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet. 2015;8:383-388. PMID 25613431. doi:10.1161/CIRCGENETICS.114.000950
  11. Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. Int J Cardiol. 2007;114:303-308. PMID 16831475. doi:10.1016/j.ijcard.2005.11.116
  12. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146:e334-e482. PMID 36322642. doi:10.1161/CIR.0000000000001106
  13. Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839-1847. PMID 26436523. doi:10.1001/jamainternmed.2015.5389
  14. Lee CC, Lee MG, Hsieh R, et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018;72:1369-1378. PMID 30213330. doi:10.1016/j.jacc.2018.06.067
  15. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. PMID 29519881. doi:10.1136/bmj.k678
  16. Dong YH, Chang CH, Wang JL, et al. Association of infections and use of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180:1587-1595. PMID 32897358. doi:10.1001/jamainternmed.2020.4192
  17. Gopalakrishnan C, Bykov K, Fischer MA, et al. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180:1596-1605. PMID 32897307. doi:10.1001/jamainternmed.2020.4199
  18. Doyle JJ, Doyle AJ, Wilson NK, et al. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. Elife. 2015;4:e08648. PMID 26506064. doi:10.7554/eLife.08648
  19. Sato T, Arakawa M, Tashima Y, et al. Statins reduce thoracic aortic aneurysm growth in Marfan syndrome mice via inhibition of the Ras-induced ERK signaling pathway. J Am Heart Assoc. 2018;7:e008543. PMID 30571378. doi:10.1161/JAHA.118.008543
  20. Hatzaras I, Tranquilli M, Coady M, et al. Weight lifting and aortic dissection: more evidence for a connection. Cardiology. 2007;107:103-106. PMID 16847387. doi:10.1159/000094530
  21. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms. Ann Thorac Surg. 2002;73:17-27. PMID 11834007. doi:10.1016/s0003-4975(01)03236-2